Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1977 1
1978 1
1992 2
2001 1
2004 2
2005 1
2006 2
2014 1
2015 1
2020 1
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
 Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L, Eze C, Taugner J, Nieto A, Hofstetter K, Kröninger S, Guggenberger J, Kenndoff S, Flörsch B, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Käsmann L, et al. Among authors: hofstetter k. J Cancer Res Clin Oncol. 2023 Aug;149(10):7393-7403. doi: 10.1007/s00432-023-04654-w. Epub 2023 Mar 20. J Cancer Res Clin Oncol. 2023. PMID: 36939927 Free PMC article.
Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports.
Manapov F, Nieto A, Käsmann L, Taugner J, Kenndoff S, Flörsch B, Guggenberger J, Hofstetter K, Kröninger S, Lehmann J, Kravutske H, Pelikan C, Belka C, Eze C. Manapov F, et al. Among authors: hofstetter k. Expert Opin Investig Drugs. 2023 Mar;32(3):187-200. doi: 10.1080/13543784.2023.2179479. Epub 2023 Feb 22. Expert Opin Investig Drugs. 2023. PMID: 36780358
First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis.
Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Hofstetter K, et al. Strahlenther Onkol. 2023 Nov 17. doi: 10.1007/s00066-023-02175-6. Online ahead of print. Strahlenther Onkol. 2023. PMID: 37975883
18 results